JP2024525709A - 脂質ナノエマルション粒子に吸着したｒｎａとその製剤 - Google Patents

脂質ナノエマルション粒子に吸着したｒｎａとその製剤 Download PDF

Info

Publication number
JP2024525709A
JP2024525709A JP2024501633A JP2024501633A JP2024525709A JP 2024525709 A JP2024525709 A JP 2024525709A JP 2024501633 A JP2024501633 A JP 2024501633A JP 2024501633 A JP2024501633 A JP 2024501633A JP 2024525709 A JP2024525709 A JP 2024525709A
Authority
JP
Japan
Prior art keywords
rna
formulation
mrna
carrier
nanocarriers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501633A
Other languages
English (en)
Japanese (ja)
Inventor
サンジェイ シン，
スワルネンドゥ カヴィラジ，
アジェイ シン，
アルジュン シン ラグワンシ，
パヴァン カルディル，
シャル シュクラ，
アイシュワリヤー クルカルニ，
プラビーン アグラワル，
スニル ラウト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gennova Biopharmaceuticals Ltd
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of JP2024525709A publication Critical patent/JP2024525709A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024501633A 2021-07-13 2022-07-08 脂質ナノエマルション粒子に吸着したｒｎａとその製剤 Pending JP2024525709A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121031414 2021-07-13
IN202121031414A IN202121031414A (enExample) 2021-07-13 2021-07-13
PCT/IN2022/050624 WO2023286076A1 (en) 2021-07-13 2022-07-08 Rna adsorbed onto lipid nano-emulsion particles and its formulations.

Publications (1)

Publication Number Publication Date
JP2024525709A true JP2024525709A (ja) 2024-07-12

Family

ID=84920187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501633A Pending JP2024525709A (ja) 2021-07-13 2022-07-08 脂質ナノエマルション粒子に吸着したｒｎａとその製剤

Country Status (11)

Country Link
US (1) US20240325522A1 (enExample)
EP (1) EP4351521A4 (enExample)
JP (1) JP2024525709A (enExample)
KR (1) KR20240035836A (enExample)
AU (1) AU2022310435A1 (enExample)
CA (1) CA3226213A1 (enExample)
CL (1) CL2024000120A1 (enExample)
CO (1) CO2024000205A2 (enExample)
IN (1) IN202121031414A (enExample)
WO (1) WO2023286076A1 (enExample)
ZA (1) ZA202400149B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023094713A2 (en) * 2021-11-29 2023-06-01 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024261766A1 (en) * 2023-06-23 2024-12-26 Gennova Biopharmaceuticals Ltd. Lyophilised vaccine formulation
EP4734962A1 (en) * 2023-06-29 2026-05-06 RIGImmune Inc. Novel formulations
WO2026093528A1 (en) * 2024-10-31 2026-05-07 Etherna Immunotherapies Nv A purification of rna by flowthrough chromatography

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522841A (ja) * 2011-07-06 2014-09-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
JP2020524143A (ja) * 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522841A (ja) * 2011-07-06 2014-09-08 ノバルティス アーゲー カチオン性水中油型エマルジョン
JP2020524143A (ja) * 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 45, JPN6026021737, 2015, pages 376 - 379, ISSN: 0005871827 *
MOLECULAR THERAPY, vol. 22, no. 12, JPN6026021736, 2014, pages 2118 - 2129, ISSN: 0005871828 *

Also Published As

Publication number Publication date
IN202121031414A (enExample) 2023-01-13
EP4351521A4 (en) 2025-12-10
CL2024000120A1 (es) 2024-08-16
ZA202400149B (en) 2024-08-28
AU2022310435A1 (en) 2024-01-25
KR20240035836A (ko) 2024-03-18
CO2024000205A2 (es) 2024-01-25
US20240325522A1 (en) 2024-10-03
EP4351521A1 (en) 2024-04-17
CA3226213A1 (en) 2023-01-19
WO2023286076A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US20240325522A1 (en) Rna adsorbed onto lipid nano-emulsion particles and its formulations
US20240207392A1 (en) Epstein-barr virus mrna vaccines
US20220378904A1 (en) Hmpv mrna vaccine composition
US20240293534A1 (en) Coronavirus glycosylation variant vaccines
TW202305140A (zh) 多價ｒｎａ組合物中ｒｎａ種類之鑑定及比率測定方法
US20230355743A1 (en) Multi-proline-substituted coronavirus spike protein vaccines
WO2022221336A1 (en) Respiratory syncytial virus mrna vaccines
WO2021211343A1 (en) Zika virus mrna vaccines
WO2022266010A1 (en) Mrna vaccines encoding flexible coronavirus spike proteins
CN110714015A (zh) 一种mRNA狂犬病疫苗
JP2018537521A (ja) 広域インフルエンザウイルスワクチン
US20240091343A1 (en) Technology platform of uncapped-linear mrna with unmodified uridine
CN114507675A (zh) 一种新型冠状病毒mRNA疫苗及其制备方法
US20250243496A1 (en) Vector for generating a circular rna
US20240327847A1 (en) Compositions and methods for rna affinity
CN116200403A (zh) 预防突变株的新型冠状病毒mRNA疫苗
CN117205309B (zh) 一种流感免疫原组合物和制备方法及其用途
US20250127870A1 (en) mRNA Vaccines Against Hantavirus
CN118510896A (zh) 用于在变性条件下富集环状rna的方法
WO2025019352A2 (en) Mers-cov mrna vaccines
EA051673B1 (ru) Рнк, адсорбированная на частицах наноэмульсии липидов, и ее композиции
KR20250145021A (ko) 핵산 분자
WO2024261766A1 (en) Lyophilised vaccine formulation
TW202340229A (zh) 冠狀病毒免疫原組成物及其用途
KR102918706B1 (ko) mRNA 백신 및 치료제의 제조를 위한 변형된 RNA

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260601